Morningstar

Bristol Myers to Unite R&D Organization Under Cristian Massacesi

Provided by Dow Jones

By Colin Kellaher

Bristol Myers Squibb is bringing its research and development operations together in a bid to accelerate the drugmaker's pipeline.

Bristol Myers on Thursday said Cristian Massacesi, currently executive vice president, chief medical officer and head of development, will lead the unified, end-to-end R&D organization, effective Jan. 1, while Robert Plenge, executive vice president and chief research officer, will depart.

Plenge, who joined Bristol Myers as part of its 2019 Celgene acquisition, will stay on in an advisory capacity through March to assist with the transition, the Princeton, N.J., company said.

Bristol Myers said it expects the new structure will more closely connect its scientific and clinical expertise across R&D, accelerate decision making and ultimately enhance portfolio execution.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

November 12, 2026 08:07 ET (13:07 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

4 Growth Stocks to Buy While They’re Still Undervalued

Plus, the outlook for the AI trade after last week’s selloff.
David Sekera, CFA and Sarah Hansen

3 of the Best Core Stocks to Own

These core stocks with wide economic moats are good long-term investments if you can buy them at a discount.
Susan Dziubinski

The 10 Best Companies to Invest in Now

The stocks of these high-quality companies look cheap today.
Tori Brovet

3 Great New ETFs From 2026

These ETFs stand out from the rest.
Brendan McCann, CFA

Why Morningstar Thinks Anthropic Is Worth $1.7 Trillion

A look at how we arrive at our base-case valuation for the AI lab, along with bull and bear scenarios.
Malik Ahmed Khan, CFA

Sponsor Center

Site Index
United States Flag United States

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.